Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants.

Deck BL, Xie SX, Choi G, Rick J, Siderowf A, Rudovsky S, Chen-Plotkin A, Duda JE, Morley JF, Dahodwala N, Trojanowski JQ, Weintraub D.

Mov Disord Clin Pract. 2019 May 17;6(6):440-445. doi: 10.1002/mdc3.12781. eCollection 2019 Jul.

PMID:
31392244
2.

Early and Accurate Identification of Parkinson Disease Among US Veterans.

Mantri S, Duda JE, Morley JF.

Fed Pract. 2019 Jun;36(Suppl 4):S18-S23.

3.

Understanding physical activity in Veterans with Parkinson disease: A mixed-methods approach.

Mantri S, Wood S, Duda JE, Morley JF.

Parkinsonism Relat Disord. 2019 Apr;61:156-160. doi: 10.1016/j.parkreldis.2018.10.023. Epub 2018 Oct 23.

PMID:
31036158
4.

Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

Coughlin DG, Petrovitch H, White LR, Noorigian J, Masaki KH, Ross GW, Duda JE.

Parkinsonism Relat Disord. 2019 Mar 28. pii: S1353-8020(19)30183-X. doi: 10.1016/j.parkreldis.2019.03.023. [Epub ahead of print]

PMID:
30948243
5.

Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology.

Ross GW, Abbott RD, Petrovitch H, Duda JE, Tanner CM, Zarow C, Uyehara-Lock JH, Masaki KH, Launer LJ, Studabaker WB, White LR.

Mov Disord. 2019 Feb;34(2):228-235. doi: 10.1002/mds.27594. Epub 2018 Dec 30.

6.

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.

Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, McMillan CT, Wolk DA, Akhtar RS, Hurtig HI, Branch Coslett H, Hamilton RH, Siderowf AD, Duda JE, Rascovsky K, Lee EB, Lee VM, Grossman M, Trojanowski JQ, Irwin DJ.

Ann Neurol. 2019 Feb;85(2):259-271. doi: 10.1002/ana.25392. Epub 2019 Jan 7.

7.

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.

Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM, Trojanowski JQ.

Brain. 2018 Jul 1;141(7):2181-2193. doi: 10.1093/brain/awy146.

8.

Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.

Struzyna LA, Browne KD, Brodnik ZD, Burrell JC, Harris JP, Chen HI, Wolf JA, Panzer KV, Lim J, Duda JE, España RA, Cullen DK.

J Tissue Eng Regen Med. 2018 Jul;12(7):1702-1716. doi: 10.1002/term.2698. Epub 2018 Jun 3.

9.

Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders.

Ugras S, Daniels MJ, Fazelinia H, Gould NS, Yocum AK, Luk KC, Luna E, Ding H, McKennan C, Seeholzer S, Martinez D, Evans P, Brown D, Duda JE, Ischiropoulos H.

EBioMedicine. 2018 May;31:307-319. doi: 10.1016/j.ebiom.2018.05.007.

10.

Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease.

Roalf DR, Rupert P, Mechanic-Hamilton D, Brennan L, Duda JE, Weintraub D, Trojanowski JQ, Wolk D, Moberg PJ.

J Neurol. 2018 Jun;265(6):1365-1375. doi: 10.1007/s00415-018-8841-8. Epub 2018 Apr 4.

11.

Physical Activity in Early Parkinson Disease.

Mantri S, Fullard ME, Duda JE, Morley JF.

J Parkinsons Dis. 2018;8(1):107-111. doi: 10.3233/JPD-171218.

12.

CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.

Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M, Trojanowski JQ.

Neurology. 2018 Mar 20;90(12):e1038-e1046. doi: 10.1212/WNL.0000000000005166. Epub 2018 Feb 21.

13.

Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test.

Morley JF, Cohen A, Silveira-Moriyama L, Lees AJ, Williams DR, Katzenschlager R, Hawkes C, Shtraks JP, Weintraub D, Doty RL, Duda JE.

NPJ Parkinsons Dis. 2018 Jan 15;4:2. doi: 10.1038/s41531-017-0039-8. eCollection 2018.

14.

Statins and Cognition in Parkinson's Disease.

Deck BL, Rick J, Xie SX, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Trojanowski JQ, Weintraub D.

J Parkinsons Dis. 2017;7(4):661-667. doi: 10.3233/JPD-171113.

15.

Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease.

Fullard ME, Morley JF, Duda JE.

Neurosci Bull. 2017 Oct;33(5):515-525. doi: 10.1007/s12264-017-0170-x. Epub 2017 Aug 22. Review.

16.

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K.

Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. Review.

17.

Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis.

Brennan L, Devlin KM, Xie SX, Mechanic-Hamilton D, Tran B, Hurtig HH, Chen-Plotkin A, Chahine LM, Morley JF, Duda JE, Roalf DR, Dahodwala N, Rick J, Trojanowski JQ, Moberg PJ, Weintraub D.

J Parkinsons Dis. 2017;7(2):385-395. doi: 10.3233/JPD-171081.

18.

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.

Pont-Sunyer C, Tolosa E, Caspell-Garcia C, Coffey C, Alcalay RN, Chan P, Duda JE, Facheris M, Fernández-Santiago R, Marek K, Lomeña F, Marras C, Mondragon E, Saunders-Pullman R, Waro B; LRRK2 Cohort Consortium.

Mov Disord. 2017 May;32(5):726-738. doi: 10.1002/mds.26964. Epub 2017 Mar 28.

PMID:
28370517
19.

Rapid neuroinflammatory response localized to injured neurons after diffuse traumatic brain injury in swine.

Wofford KL, Harris JP, Browne KD, Brown DP, Grovola MR, Mietus CJ, Wolf JA, Duda JE, Putt ME, Spiller KL, Cullen DK.

Exp Neurol. 2017 Apr;290:85-94. doi: 10.1016/j.expneurol.2017.01.004. Epub 2017 Jan 9.

20.

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ.

Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.

21.

Olfactory Impairment Predicts Underlying Dopaminergic Deficit in Presumed Drug-Induced Parkinsonism.

Morley JF, Cheng G, Dubroff JG, Wood S, Wilkinson JR, Duda JE.

Mov Disord Clin Pract. 2016 Nov 28;4(4):603-606. doi: 10.1002/mdc3.12458. eCollection 2017 Jul-Aug.

22.

A Porcine Model of Traumatic Brain Injury via Head Rotational Acceleration.

Cullen DK, Harris JP, Browne KD, Wolf JA, Duda JE, Meaney DF, Margulies SS, Smith DH.

Methods Mol Biol. 2016;1462:289-324. doi: 10.1007/978-1-4939-3816-2_17.

23.

Arguing against the proposed definition changes of PD.

Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP.

Mov Disord. 2016 Nov;31(11):1619-1622. doi: 10.1002/mds.26721. Epub 2016 Aug 5.

24.

High patient satisfaction with telehealth in Parkinson disease: A randomized controlled study.

Wilkinson JR, Spindler M, Wood SM, Marcus SC, Weintraub D, Morley JF, Stineman MG, Duda JE.

Neurol Clin Pract. 2016 Jun;6(3):241-251.

25.

Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.

Marras C, Alcalay RN, Caspell-Garcia C, Coffey C, Chan P, Duda JE, Facheris MF, Fernández-Santiago R, Ruíz-Martínez J, Mestre T, Saunders-Pullman R, Pont-Sunyer C, Tolosa E, Waro B; LRRK2 Cohort Consortium.

Mov Disord. 2016 Aug;31(8):1192-202. doi: 10.1002/mds.26614. Epub 2016 Apr 19.

PMID:
27091104
26.

Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease.

Roalf DR, Moore TM, Wolk DA, Arnold SE, Mechanic-Hamilton D, Rick J, Kabadi S, Ruparel K, Chen-Plotkin AS, Chahine LM, Dahodwala NA, Duda JE, Weintraub DA, Moberg PJ.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1303-1310. doi: 10.1136/jnnp-2015-312723. Epub 2016 Apr 12.

27.

The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease.

Brennan L, Siderowf A, Rubright JD, Rick J, Dahodwala N, Duda JE, Hurtig H, Stern M, Xie SX, Rennert L, Karlawish J, Shea JA, Trojanowski JQ, Weintraub D.

Parkinsonism Relat Disord. 2016 Apr;25:21-6. doi: 10.1016/j.parkreldis.2016.02.020. Epub 2016 Feb 21.

28.

Olfactory impairment predicts cognitive decline in early Parkinson's disease.

Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF.

Parkinsonism Relat Disord. 2016 Apr;25:45-51. doi: 10.1016/j.parkreldis.2016.02.013. Epub 2016 Feb 19.

29.

Central nervous system uptake of intranasal glutathione in Parkinson's disease.

Mischley LK, Conley KE, Shankland EG, Kavanagh TJ, Rosenfeld ME, Duda JE, White CC, Wilbur TK, De La Torre PU, Padowski JM.

NPJ Parkinsons Dis. 2016 Feb 25;2:16002. doi: 10.1038/npjparkd.2016.2. eCollection 2016.

30.

Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.

Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van Deerlin VM, Lee EB, Arnold SE, Duda JE, Hurtig H, Lee VM, Adler CH, Beach TG, Trojanowski JQ.

Acta Neuropathol. 2016 Mar;131(3):393-409. doi: 10.1007/s00401-015-1526-9. Epub 2015 Dec 31.

31.

Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis.

Brennan L, Pantelyat A, Duda JE, Morley JF, Weintraub D, Wilkinson JR, Moberg PJ.

Mov Disord Clin Pract. 2015 Dec 7;3(2):161-167. doi: 10.1002/mdc3.12264. eCollection 2016 Mar-Apr.

32.

Dietary modifications in Parkinson's disease: A neuroprotective intervention?

Shah SP, Duda JE.

Med Hypotheses. 2015 Dec;85(6):1002-5. doi: 10.1016/j.mehy.2015.08.018. Epub 2015 Sep 6.

PMID:
26364043
33.

Longitudinal study of normal cognition in Parkinson disease.

Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D.

Neurology. 2015 Oct 13;85(15):1276-82. doi: 10.1212/WNL.0000000000002001. Epub 2015 Sep 11.

34.

Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire.

Brennan L, Siderowf A, Rubright JD, Rick J, Dahodwala N, Duda JE, Hurtig H, Stern M, Xie SX, Rennert L, Karlawish J, Shea JA, Trojanowski JQ, Weintraub D.

Mov Disord. 2016 Jan;31(1):126-34. doi: 10.1002/mds.26339. Epub 2015 Aug 7.

35.

Caregiver report of apathy predicts dementia in Parkinson's disease.

Fitts W, Weintraub D, Massimo L, Chahine L, Chen-Plotkin A, Duda JE, Hurtig HI, Rick J, Trojanowski JQ, Dahodwala N.

Parkinsonism Relat Disord. 2015 Aug;21(8):992-5. doi: 10.1016/j.parkreldis.2015.06.009. Epub 2015 Jun 9.

36.

Continuous non-invasive monitoring to detect covert autonomic dysfunction in Parkinson's disease.

Hellman AM, Shah SP, Pawlowski SM, Duda JE, Morley JF.

Parkinsonism Relat Disord. 2015 Jul;21(7):723-8. doi: 10.1016/j.parkreldis.2015.04.016. Epub 2015 Apr 23.

PMID:
25940998
37.

Caregiver tele-support group for Parkinson's disease: A pilot study.

Shah SP, Glenn GL, Hummel EM, Hamilton JM, Martine RR, Duda JE, Wilkinson JR.

Geriatr Nurs. 2015 May-Jun;36(3):207-11. doi: 10.1016/j.gerinurse.2015.02.002. Epub 2015 Mar 3.

PMID:
25744558
38.

Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.

Nabli F, Ben Sassi S, Amouri R, Duda JE, Farrer MJ, Hentati F.

Mov Disord. 2015 Feb;30(2):253-8. doi: 10.1002/mds.26097. Epub 2014 Dec 9.

PMID:
25487881
39.

Taste function in early stage treated and untreated Parkinson's disease.

Doty RL, Nsoesie MT, Chung I, Osman A, Pawasarat I, Caulfield J, Hurtig H, Silas J, Dubroff J, Duda JE, Ying GS, Tekeli H, Leon-Sarmiento FE.

J Neurol. 2015 Mar;262(3):547-57. doi: 10.1007/s00415-014-7589-z. Epub 2014 Dec 6.

PMID:
25480568
40.

Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease.

van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, Chahine LM, Dahodwala N, Trojanowski JQ, Roalf DR, Moberg PJ, Weintraub D.

Mov Disord. 2014 Dec;29(14):1809-15. doi: 10.1002/mds.26062. Epub 2014 Nov 7.

41.

Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, Minger J, Weintraub D.

Neurology. 2014 Aug 26;83(9):826-33. doi: 10.1212/WNL.0000000000000729. Epub 2014 Jul 18.

42.

The spectrum of cognitive impairment in Lewy body diseases.

Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE.

Mov Disord. 2014 Apr 15;29(5):608-21. doi: 10.1002/mds.25866. Review.

43.

Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.

Morley JF, Pawlowski SM, Kesari A, Maina I, Pantelyat A, Duda JE.

Parkinsonism Relat Disord. 2014 Jul;20(7):738-42. doi: 10.1016/j.parkreldis.2014.03.024. Epub 2014 Apr 1.

PMID:
24742370
44.

Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.

Trinh J, Amouri R, Duda JE, Morley JF, Read M, Donald A, Vilariño-Güell C, Thompson C, Szu Tu C, Gustavsson EK, Ben Sassi S, Hentati E, Zouari M, Farhat E, Nabli F, Hentati F, Farrer MJ.

Neurobiol Aging. 2014 May;35(5):1125-31. doi: 10.1016/j.neurobiolaging.2013.11.015. Epub 2013 Nov 22.

PMID:
24355527
45.

Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease.

Morley JF, Duda JE.

J Parkinsons Dis. 2014;4(2):169-73. doi: 10.3233/JPD-130299. Review.

PMID:
24284418
46.

Lower urinary tract symptoms in men with Parkinson disease.

Robinson JP, Bradway CW, Bunting-Perry L, Avi-Itzhak T, Mangino M, Chittams J, Duda JE.

J Neurosci Nurs. 2013 Dec;45(6):382-92; quiz E1-2. doi: 10.1097/JNN.0b013e3182a3cf67.

PMID:
24217149
47.

Daytime sleepiness is associated with falls in Parkinson's disease.

Spindler M, Gooneratne NS, Siderowf A, Duda JE, Cantor C, Dahodwala N.

J Parkinsons Dis. 2013 Jan 1;3(3):387-91. doi: 10.3233/JPD-130184.

48.

Laser light visual cueing for freezing of gait in Parkinson disease: A pilot study with male participants.

Bunting-Perry L, Spindler M, Robinson KM, Noorigian J, Cianci HJ, Duda JE.

J Rehabil Res Dev. 2013;50(2):223-30.

49.

Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.

Chahine LM, Daley J, Horn S, Duda JE, Colcher A, Hurtig H, Cantor C, Dahodwala N.

Parkinsonism Relat Disord. 2013 Oct;19(10):859-63. doi: 10.1016/j.parkreldis.2013.05.009. Epub 2013 Jun 14.

PMID:
23751512
50.

Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial.

Weintraub D, Duda JE, Carlson K, Luo P, Sagher O, Stern M, Follett KA, Reda D, Weaver FM; CSP 468 Study Group.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1113-8. doi: 10.1136/jnnp-2012-304396. Epub 2013 May 10.

Supplemental Content

Support Center